Ocular Therapeutix™ Submits Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery

BEDFORD, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank"gt;$OCULlt;/agt; lt;a href="https://twitter.com/hashtag/OCUTX?src=hash" target="_blank"gt;#OCUTXlt;/agt;--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for DEXTENZA (dexamethasone ophthalmic insert). The sNDA filing seeks to expand the current indication for DEXTENZA to include the treatment of o

Full Story →